Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
KamadaKMDA -0.85%86 OCF Margin % is 32.90% as of Jun. 2026, which is 182% above its 10-year median of 11.67. GuruFocus rates KMDA with a GF Score™ of 86/100 and a GF Value™ of $8.60 (Fairly Valued). The stock has 1 warning sign investors should review. Among 963 Drug Manufacturers companies, Kamada ranks better than 75.08% on this metric.
The historical data trend for Kamada's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kamada's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kamada OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kamada's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Kamada's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kamada (KMDA) has a OCF Margin % of 32.90% as of Jun. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Kamada and its competitors. This is 182% above median its historical median of 11.67. According to the industry distribution chart, Kamada ranks #240 out of 963 companies in the Drug Manufacturers industry, placing it in the top 24.9%.
Is Kamada's OCF Margin % too high?
Kamada's current OCF Margin % of 32.90% is 182% above median its 10-year median of 11.67. The Drug Manufacturers industry median OCF Margin % is 10.22. Kamada's value of 32.90% is 221.9% above this industry median. Based on the distribution chart, Kamada ranks #240 out of 963 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Kamada has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Kamada's OCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Kamada ranks #240 out of 963 companies for OCF Margin %. This places Kamada in the top 25% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 10.22. Kamada's value of 32.90% is 221.9% above this benchmark. While the company's 10-year median is 11.67 vs. the industry median of 10.22, Kamada has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 10.22, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kamada's current OCF Margin % of 32.90% is 221.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Kamada and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 10.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kamada's current OCF Margin % is 32.90%, which is 182% above median its own 10-year median of 11.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kamada stock overvalued right now?
Based on GuruFocus' analysis, Kamada (KMDA) is currently considered Fairly Valued. The stock's GF Value™ is $8.60, compared to a current price of $8.20 — trading 4.7% below its estimated fair value. The current OCF Margin % is 32.90%, which is 182% above median its 10-year median of 11.67 and 221.9% above the Drug Manufacturers industry median of 10.22. Kamada's overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Kamada (KMDA), the current OCF Margin % is 32.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kamada (KMDA) Overvalued in 2026?
Based on GuruFocus' analysis, Kamada stock appears to be undervalued.
The current stock price of $8.20 is trading 4.7% below its estimated GF Value™ of $8.60.
GuruFocus considers Kamada to be Fairly Valued.
Key valuation signals for KMDA:
OCF Margin %: 32.90% (182% above median its 10-year median of 11.67)
GF Value™: $8.60 vs. price of $8.20 (4.7% below fair value)
Industry Position: 221.9% above the Drug Manufacturers median (#240 of 963)
No single metric tells the full story. See the KMDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
86GF Score
Get the complete analysis for KMDA
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KMDA has been successfully added to your 
